Supplement
Aniracetam is a lab-made compound from the racetam family that is thought to influence glutamate signaling, a chemical system involved in learning and memory. In people with mild dementia, research found thinking scores held steady over 6 to 12 months, did better than cholinesterase inhibitor drugs at 6 months, and mood and daily functioning improved at 3 months. Still, the evidence is limited, drawn from about 276 people, with effects small to moderate.
- Updated
- How we grade
- 1 study cited
- Best evidence
- Grade C
- Conditions studied
- 2
- Outcomes
- 3
- Graded outcomes
- 0030
Evidence by condition
- Strong
- Moderate
- Limited
- Very limited
Mild Cognitive Impairmentdementia
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Cognitive Function (MMSE) Maintained cognitive parameters at 6-12 months; better than ChEIs at 6 months in mild dementia (MMSE 15-25) | Improves (the measure goes up) | Moderate effect | 276 people |
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Emotional State Significantly improved emotional state at 3 months | Improves (the measure goes up) | Moderate effect | 276 people | |||
| Functionality Improved functionality at 3 months vs cholinesterase inhibitors | Improves (the measure goes up) | Small effect | 276 people |
Key findings
- Cognitive Function (MMSE)Improves (the measure goes up)
- Emotional StateImproves (the measure goes up)
- FunctionalityImproves (the measure goes up)
Studies cited
1 study from PubMed